接受指南导向药物治疗的慢性肾脏病患者特征与心肾结局:DISCOVER CKD研究启示
DISCOVER CKD为多国观察性队列研究,前瞻性纳入1052例成人慢性肾脏病患者,评估基线指南导向药物治疗(GDMT)使用与15个月内结局的关系。在3-4期慢性肾脏病患者中,GDMT使用与复合肾脏结局发生率显著降低相关(倾向评分加权HR 0.48,95%CI 0.27-0.84,P=.01),全因死亡与新发心血管事件复合终点及全因住院率无显著差异。
要点
- 基线61.1%患者接受GDMT,其中仅RASi 496例、仅SGLT2i 25例、两者联用122例。
- 3-4期慢性肾脏病患者中,GDMT使用与复合肾脏结局风险降低相关(PS加权HR 0.48)。
- GDMT与全因死亡及新发心血管事件复合终点、全因住院率无显著差异。
核心结论
- 在真实世界慢性肾脏病患者中,GDMT使用与肾脏不良结局减少相关,凸显需解决GDMT实施中的巨大差距。
研究设计与样本
- DISCOVER CKD(NCT04034992)为多国观察性队列研究,前瞻性队列入组时间为2019年9月至2022年6月。
- 前瞻性纳入1052例成人慢性肾脏病患者,年龄62.5±13.6岁,女性占36.9%。
- 按基线GDMT使用情况评估患者特征及最长15个月的结局,采用逆概率治疗加权法控制混杂变量并估计GDMT使用效应。
主要发现
- 多数患者为CKD 3a期(31.6%)或3b期(29.3%),8.4%正在接受透析。
- 基线时643例(61.1%)接受GDMT,包括仅RASi 496例、仅SGLT2i 25例、两者联用122例,范围从42.7%(美国)至82.2%(西班牙、瑞典)。
- 接受GDMT的患者较未接受者合并症负担更高。
- 在CKD 3-4期患者中,GDMT使用与复合肾脏结局发生率显著降低相关(PS加权HR 0.48,95%CI 0.27-0.84,P=.01)。
- 接受GDMT与未接受者相比,全因死亡及新发心血管事件复合终点(PS加权HR 0.50,95%CI 0.23-1.09,P=.08)及全因住院率(PS加权率比0.78,95%CI 0.52-1.16,P=.216)无显著差异。
关键数值与推荐
- 复合肾脏结局定义:开始透析、肾移植、估算肾小球滤过率<15 mL/min/1.73 m2或归因于肾脏原因的死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: In clinical trials, renin-angiotensin system inhibitors (RASi) and sodium-glucose co-transporter-2 inhibitors (SGLT2i), herein referred to as guideline-directed medical therapy (GDMT), alone or in combination, provide cardio-renal protection in patients with chronic kidney disease (CKD). However, data from real-world clinical practice on the impact of GDMT on clinical outcomes are limited. METHODS: DISCOVER CKD (NCT04034992) is a multinational, observational cohort study in adults with CKD. We used the prospective cohort (enrollment: September 2019 to June 2022) to assess patient characteristics and outcomes up to 15 months by baseline GDMT use, including: a composite renal outcome (initiation of dialysis, kidney transplantation, estimated glomerular filtration rate <15 mL/min/1.73 m2 or death attributable to renal causes); all-cause mortality and new cardiovascular (CV) events; and all-cause hospitalization. Inverse probability of treatment weighting method was employed in controlling confounding variables and estimating the effect of GDMT use. RESULTS: Of 1052 prospectively enrolled patients (62.5 ± 13.6 years, 36.9% female), most had CKD stage 3a (31.6%) or 3b (29.3%); 8.4% were receiving dialysis. At baseline, 643 (61.1%) were receiving GDMT [RASi only, n = 496; SGLT2i only, n = 25; both, n = 122; range 42.7% (USA) to 82.2% (Spain, Sweden)]. Patients receiving GDMT had a higher comorbidity burden than those without GDMT. In patients with CKD stage 3-4, GDMT use was associated with significantly lower incidence of the composite renal outcome [propensity score (PS)-weighted hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.27-0.84, P = .01]. There was no significant difference between those receiving GDMT versus not in composite all-cause mortality and new CV events (PS-weighted HR 0.50, 95% CI 0.23-1.09; P = .08) or all-cause hospitalization rate (PS-weighted rate ratio 0.78, 95% CI 0.52-1.16; P = .216). CONCLUSIONS: GDMT use was associated with reduced adverse renal outcomes in real-world patients with CKD, underscoring the need to address large gaps in GDMT implementation.
引用
- Pecoits-Filho R, Kanda E, Kashihara N, et al. Characteristics and cardio-renal outcomes in patients with CKD receiving guideline-directed medical therapy: insights from DISCOVER CKD. Nephrol Dial Transplant. 2026. PMID: 40972017. doi:10.1093/ndt/gfaf175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。